南方财经 21世纪经济报道记者袁思杰香港报道 在粤港澳大湾区，一条跨城协作的创科纽带正在形成：香港科学园的实验室里，前沿黑科技悄然诞生； 深圳的产业园中，科研成果快速转化为市场产品；东莞的厂房内，精密零部件高效组装成型；广州的物 流网络里，创新产品运往全球各地。 据世界知识产权组织今年9月发布的最新《2025年全球创新指数报告》，"广深港"创新集群首次登顶全 球百强创新集群排行榜榜首，实现从连续五年全球第二到第一的历史性跨越。 这一成绩的背后，是大湾区打破地域壁垒、整合创新资源的持续探索。从光谱仪国产化到AI健康筛 查，从具身智能机器人到6G前沿技术，一批初创企业与科研团队在湾区沃土上快速成长，用技术突破 见证协作力量，用产业融合诠释湾区精神。 粤港澳大湾区的创科协作，本质上是一场精准的城市分工与资源整合。 香港凭借顶尖科研实力聚焦基础研发，深圳依托产业优势推动成果转化，东莞以精密制造赋能量产落 地，广州、江门等城市则提供物流、政策等配套支持，形成了覆盖 "研发—转化—制造—销售" 的全生 命周期闭环体系，让创新想法能够快速落地生根。 威视佰科CEO刘玮对此有着深刻体会。2020 年受邀担任香港大学兼职教授后 ...

文章来源： 嘉思特医疗 转载要求：可以直接转载，请在文首注明来源 嘉思特医疗磐石自加压3D分区骨小梁生物型膝关节假体凭借四大创新设计，开启膝关节表面生物固定新时 代： 创新点一： 自加压机械稳定技术 ： 提供主动机械锁定，实现超越传统压配的即刻稳定(微动<100um)，为骨整 合奠定基础。 2025年11月14日12时28分， 国家重点小巨人企业嘉思特医疗器材（天津）股份有限公司 获批的 国家创新医疗 器械 产品"磐石自加压3D分区骨小梁生物型膝关节假体"在 天津 国家会展中心举办的第17届COA学术大会荣耀 上市！ 行业21位头部专家亲临现场，共同启动新品上市发布仪式，他们分别是： 西安交通大学第二附属医院 王坤 正教授 ， 天津医院 马信龙教授 ， 新疆医科大学第一附属医院 曹力教授 ， 浙江大学医学院附属第一医院 胡懿郃教授 ， 福建医科大学附属第一医院 张文明教授 ， 四川大学华西医院 周宗科教授 ， 重庆医科大学 附属第一医院 黄伟教授 ， 北京大学第三医院 田华教授 ， 浙江大学医学院附属第二医院 严世贵教授 ，哈 尔滨医科大学附属第二医院 吕松岑教授 ，辽宁省人民医院 白希壮教授 ，中国医科大学 ...

Core Insights - The collaboration between the Luohu District Government and Shenzhen University of Technology aims to establish the "Shenzhen University of Technology Luohu Medical Center" and "Shenzhen University of Technology Luohu Medical Industry Incubation Base" to enhance the life and health industry through innovation in systems and mechanisms [1][2] Group 1: Collaboration Details - The partnership will create a comprehensive "medical research, production, and talent" complex, promoting deep integration of industry, academia, and research [1] - The "one center, one base" initiative is located in the Health Industry Park at the Zhifeng Building in Luohu District, designed to foster an ecosystem for life and health industry services [1] Group 2: Talent and Resource Sharing - The medical center will implement a dual-hire Principal Investigator (PI) talent system to attract top scholars from Shenzhen University of Technology and clinical experts from Luohu, facilitating resource sharing [1] - The collaboration will leverage clinical resources and platform advantages to establish an innovative industry incubation space and a cell therapy drug research and transformation platform [1] Group 3: Operational Model - The incubation base will adopt a "government-led, university-driven, enterprise-operated" model, with Luohu District providing industrial space and entrusting daily operations to professional service agencies [1] - The focus will be on cutting-edge fields such as AI + medical devices, medical-engineering integration, precision medicine, and cell and gene therapy, promoting the integration of medical research and industrial transformation [1][2] Group 4: Data and Impact - Luohu District's medical institutions handle over 10 million diagnoses annually and have accumulated nearly 1000TB of medical data, providing a "technology testing ground" and opportunities for first-use by enterprises [2] - Shenzhen University of Technology, as one of the first new research-oriented universities in China, has a strong capability in scientific research innovation and talent cultivation, which will further enhance the collaborative ecosystem [2]

Core Points - The establishment of the Suzhou Integration Development Center by the Chinese Microcirculation Society aims to enhance the management of chronic diseases and promote innovation in the biomedicine industry in Suzhou [1][2] - The center will focus on technology transfer, professional talent training, and the development of technical standards in the field of chronic disease screening and prevention [1] - The collaboration between the Chinese Microcirculation Society, Suzhou Science and Technology Association, and Southeast University Suzhou Research Institute is aligned with the strategic needs of high-quality development in the biomedicine sector and the "Healthy Suzhou" initiative [1] Group 1 - The center's establishment is expected to gather top expert resources and cutting-edge technological achievements to facilitate breakthroughs in microcirculation-related disease prevention and control, high-end medical device research and development, and optimization of chronic disease management systems [1] - The center aims to significantly enhance the demonstration and leading effect of "Science and Technology Innovation China" in Suzhou [1] - Since its founding in 1993, the Chinese Microcirculation Society has been deeply involved in academic research, clinical transformation, and industry-education integration in the microcirculation field [2] Group 2 - The society has established strong academic foundations and rich expert resources in areas such as cardiovascular and cerebrovascular diseases, diabetic complications, tumor microenvironments, and tissue engineering [2] - In the current year, the society has organized over 60 experts to engage with 39 local biomedicine companies and 24 research institutions and hospitals in Suzhou, resulting in 15 cooperation intentions [2] - The society has also provided professional technical guidance to 10 local enterprises [2]

Core Insights - The cumulative value of technology contracts from Beijing to Tianjin and Hebei reached 230.87 billion yuan since the start of the 14th Five-Year Plan, nearly doubling the amount from the previous five years [1] - The Beijing-Tianjin-Hebei region has collaboratively developed six key industrial chains, including new energy vehicles and robotics, enhancing industrial synergy and innovation [1][3] Company Developments - Tangshan Siwei Intelligent Technology Co., Ltd. has developed a robotic system for the delicate task of packaging fermented tofu, achieving a production rate of 4,800 units per hour, equivalent to the work of two skilled workers [3][5] - The company utilized a "shared factory" model to minimize capital investment while accessing advanced manufacturing capabilities and talent from various sources, including local universities [3][5] - The first prototype of the tofu packaging robot has passed inspection and has received multiple patents, indicating strong market potential for the broader condiment industry [5] Industry Trends - BMC Ruimait Medical Technology Co., Ltd. has successfully developed high-performance home ventilators, achieving over 3 million units sold, and has broken international technology monopolies in the process [7][8] - The company emphasizes the importance of integrating medical and engineering resources to create products tailored to local needs, enhancing the efficiency of respiratory health management [8] - The collaboration between Beijing's research institutions and Hebei's agricultural sector has led to the development of high-yield quinoa varieties, significantly improving local farmers' income [11][12]

Core Insights - BMC Ruimaite has established itself as a leading domestic enterprise in the respiratory health sector, focusing on independent research and development to overcome the challenges posed by international competitors [2][3] - The company aims to evolve from providing single devices to offering comprehensive respiratory health solutions, enhancing user experience and accessibility [3] Group 1: Company Development - BMC Ruimaite's production facility in Tianjin is actively manufacturing home ventilators, which are set to be distributed to over 100 countries and regions globally [2] - The company has made significant advancements in core technology, particularly in the development of the fan, which is considered the "heart" of the ventilator, achieving performance levels comparable to top international standards [2] Group 2: Strategic Vision - The company envisions becoming the preferred platform for global respiratory health management, leveraging its accumulated technology, products, and services to meet user needs more effectively [3] - A collaborative project involving BMC Ruimaite, its subsidiary Tianjin Yihe Jiaye, and Beijing Chaoyang Hospital has been awarded the first prize in the "Science and Technology Progress Award" by the Tianjin Science and Technology Bureau, highlighting the importance of integrating medical and engineering expertise [3]

Core Insights - BMC Ruimait, a leading domestic enterprise in the respiratory health sector, shared its strategic path and achievements in core technology breakthroughs, global market expansion, and the construction of a respiratory health ecosystem during a media communication event [1] Group 1: Technological Development and Global Competitiveness - BMC Ruimait is the only Chinese company among the top five global home ventilator manufacturers, having been established in 2001 and listed on the Shenzhen Stock Exchange in 2022, focusing on providing products and services for respiratory issues like COPD and obstructive sleep apnea [4] - The company has achieved significant technological advancements, becoming the first Chinese home ventilator brand to receive FDA certification in 2012, with 932 domestic and international patents and over 20 products certified by the FDA as of June 30, 2025 [4][7] - BMC Ruimait has sold over 3 million home ventilators and more than 10 million ventilation masks globally, demonstrating its strong market presence [4] Group 2: Innovation and Industry Standards - The company has focused on independent research and development of core technologies, particularly in the manufacturing of key components like the fan, which has reached international standards in speed, stability, and noise control [7] - BMC Ruimait has contributed to the establishment of 38 international and domestic standards, enhancing the quality of Chinese respiratory health products and increasing their competitiveness in the global market [9] Group 3: Ecosystem Development and Health Management - BMC Ruimait is expanding its capabilities from single-device solutions to comprehensive health management systems, aiming to create a global platform for respiratory health management [10] - The company has introduced innovative technologies such as "smart on-demand oxygen supply," showcasing its ability to integrate hardware and software solutions across various respiratory health applications [11] - A new "smart mobile oxygen supply solution" has been developed, which includes a range of interconnected products designed to enhance user experience and meet diverse needs [13] Group 4: Clinical Integration and Future Vision - The integration of medical and engineering practices is emphasized as essential for addressing local healthcare needs, with BMC Ruimait's products evolving from single devices to comprehensive solutions that cover hospitals, homes, and outdoor environments [14] - The company's vision aligns with modern medical principles, focusing on transitioning from disease treatment to health management, thereby improving patient quality of life and treatment adherence [14]

Core Insights - The event highlighted the importance of overcoming "bottleneck" technologies in various fields, particularly in biomedical and materials science, to drive innovation and industrial transformation [1][2]. Group 1: Biomedical Innovations - Sheng Jingwei, founder of Beijing Kunmai Medical Technology Co., shared his journey in brain imaging technology, emphasizing the need to translate physical technology into practical medical tools [2][3]. - His team developed a quantum sensor capable of detecting brain magnetic signals at one billionth of the Earth's magnetic field strength, showcasing significant advancements in medical imaging [3]. - Liu Peng from the Chinese Academy of Sciences discussed the development of synchrotron radiation sources, which have played a crucial role in combating viruses like SARS and Ebola [3][4]. Group 2: Materials Science Developments - Niu Junhui from YAN Research Metal Composite Materials (Beijing) Co., Ltd. presented the challenges and successes in the domestic development of microcrystalline silicon-aluminum materials, which are lighter and stronger than conventional aluminum alloys [4][5]. - The transition from laboratory success to industrial production involved overcoming significant technical hurdles, including achieving stable mass production of the new material [5][6]. Group 3: Educational Impact - The presentations inspired students at Capital Medical University, emphasizing the importance of integrating personal aspirations with national goals in scientific research [7]. - Students expressed a desire to contribute to key technological fields and recognized the significance of interdisciplinary skills in advancing medical engineering [7].

Group 1 - The core focus of the event was on innovative achievements in the medical-engineering integration and health sector, with the theme "Integrating Innovation for a Healthier Future" [4] - The final competition featured 131 registered projects, including 23 from the startup group and 16 from the growth group, covering areas such as biopharmaceuticals, gene therapy, and medical technology [4] - The winning project, "Spectral Imaging Flow Cytometer," received the grand prize in the startup group, while "Hezhizheng Medical Device High-end Manufacturing System Innovation Service Platform Solution" won the grand prize in the growth group [5] Group 2 - Compared to previous years, there was an increase in projects addressing difficult and rare diseases, as well as a rise in projects integrating artificial intelligence [5] - The grand prize, gold, and silver award-winning projects received cash prizes of 30,000, 10,000, and 5,000 yuan respectively, with startup group winners also receiving equity investments totaling over 200 million yuan [5] - The "Spectral Imaging Flow Cytometer" was developed to address limitations of traditional flow cytometers, which only provide numerical data and lack morphological imaging capabilities, thus enhancing the accuracy and depth of cellular analysis [5][6] Group 3 - The project has secured nearly 100 million yuan in angel round financing led by Mingxi Capital and Junlian Capital, with follow-up investment from Hubei Science and Technology Investment [6] - Last year's grand prize project, "Stem Cell Treatment for Spinal Diseases," attracted nearly 30 million yuan in investment, with over 10 projects from last year's winners completing financing [6]

Group 1 - Company Huagong Technology (000988.SZ) announced that its wholly-owned subsidiary, Wuhan Huagong Technology Investment Management Co., Ltd. (referred to as "Huagong Investment"), has signed a partnership agreement to establish the Wuhan Huagong Ruiyuan No. 2 Venture Capital Fund Partnership (Limited Partnership) with several other investment entities [1] - Huagong Investment plans to invest no more than 76.5 million yuan in the new fund, holding a 21.86% share of the fund's assets [1] - The fund aims to focus on investment opportunities in high-end equipment, intelligent manufacturing, optoelectronics, new energy, new materials, sensors, and semiconductors, as well as emerging technologies such as quantum technology, medical-engineering integration, and artificial intelligence [2]